- Home
- CUE vs RCS Comparison
CUE vs RCS Comparison
Compare CUE & RCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CUE | RCS |
|---|---|---|
| Founded | 2014 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.5M | 246.0M |
| IPO Year | 2017 | 1994 |
Fundamental Metrics
Financial Performance| Metric | CUE | RCS |
|---|---|---|
| Price | $36.51 | $4.94 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $120.00 | N/A |
| AVG Volume (30 Days) | 140.7K | ★ 154.3K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.12% |
| EPS Growth | ★ 61.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,466,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 195.75 | N/A |
| 52 Week Low | $0.17 | $4.84 |
| 52 Week High | $45.50 | $8.00 |
Technical Indicators
Market Signals| Indicator | CUE | RCS |
|---|---|---|
| Relative Strength Index (RSI) | 69.70 | 25.23 |
| Support Level | $24.35 | N/A |
| Resistance Level | $41.42 | $5.67 |
| Average True Range (ATR) | 3.24 | 0.09 |
| MACD | 1.23 | -0.03 |
| Stochastic Oscillator | 86.62 | 18.35 |
Price Performance
Historical ComparisonAbout CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.